{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T01:06:06Z","timestamp":1772154366232,"version":"3.50.1"},"reference-count":101,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T00:00:00Z","timestamp":1480636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>Antiphospholipid syndrome is an autoimmune, acquired thrombophilia diagnosed when vascular thrombosis or pregnancy morbidity are accompanied by persistent antiphospholipid antibodies. Lupus anticoagulants (LA) are one of the criteria antibodies but calibration plasmas are unavailable and they are detected by inference based on antibody behaviour in a medley of coagulation-based assays. Elevated screening tests suggest the presence of a LA, which is confirmed with mixing tests to evidence inhibition and confirmatory tests to demonstrate phospholipid-dependence. At least two screening tests of different principle must be used to account for antibody heterogeneity and controversy exists on whether assays, in addition to dilute Russell\u2019s viper venom time and activated partial thromboplastin time, should be employed. A variety of approaches to raw data manipulation and interpretation attract debate, as does inclusion or exclusion of mixing studies in circumstances where the presence of a LA is already evident from other results. Therapeutic anticoagulation compromises coagulation-based assays but careful data interpretation and use of alternative reagents can detect or exclude LA in specific circumstances, and this aspect of LA detection continues to evolve. This review focuses on the main areas of debate in LA detection.<\/jats:p>","DOI":"10.3390\/antib5040022","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T10:36:37Z","timestamp":1480674997000},"page":"22","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Current Controversies in Lupus Anticoagulant Detection"],"prefix":"10.3390","volume":"5","author":[{"given":"Gary","family":"Moore","sequence":"first","affiliation":[{"name":"Diagnostic Haemostasis &amp; Thrombosis Laboratories, Department of Haemostasis and Thrombosis, Viapath Analytics, Guy\u2019s &amp; St. Thomas\u2019 NHS Foundation Hospitals Trust, 4th floor North Wing, St. Thomas\u2019 Hospital, Westminster Bridge Road, London SE1 7EH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2016,12,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1046\/j.1365-2141.2000.02069.x","article-title":"Guidelines on the investigation and management of the antiphospholipid syndrome","volume":"109","author":"Greaves","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1177\/0961203312439335","article-title":"Standardization of antiphospholipid antibody assays. Where do we stand?","volume":"21","author":"Devreese","year":"2012","journal-title":"Lupus"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1055\/s-0032-1304715","article-title":"The future of antiphospholipid antibody testing","volume":"38","author":"Urbanus","year":"2012","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/j.1538-7836.2009.03555.x","article-title":"Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection","volume":"7","author":"Pengo","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2141.2012.09037.x","article-title":"British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome","volume":"157","author":"Keeling","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_6","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2014). Laboratory Testing for the Lupus Anticoagulant: Approved Guideline, Clinical and Laboratory Standards Institute. CLSI Document H60-A."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-0033-1364185","article-title":"Recent guidelines and recommendations for laboratory detection of lupus anticoagulants","volume":"40","author":"Moore","year":"2014","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1055\/s-0038-1648143","article-title":"Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants","volume":"65","author":"Exner","year":"1991","journal-title":"Thromb. Haemost."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/jcp.44.11.885","article-title":"Guidelines on testing for the lupus anticoagulant. Lupus Anticoagulant Working Party on behalf of the BCSH Haemostasis and Thrombosis Task Force","volume":"44","author":"Machin","year":"1991","journal-title":"J. Clin. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1055\/s-0038-1649901","article-title":"Criteria for the diagnosis of lupus anticoagulants: An update. On behalf of the Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH","volume":"74","author":"Brandt","year":"1995","journal-title":"Thromb. Haemost."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1373\/clinchem.2007.089524","article-title":"Laboratory testing for lupus anticoagulants: A review of issues affecting results","volume":"53","author":"Tripodi","year":"2007","journal-title":"Clin. Chem."},{"key":"ref_12","first-page":"98","article-title":"Sensitivity of sixteen APTT reagents for the presence of lupus anticoagulants","volume":"25","author":"Flahault","year":"1995","journal-title":"Haemostasis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1055\/s-0032-1311991","article-title":"Laboratory identification of lupus anticoagulants","volume":"38","author":"Kershaw","year":"2012","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1309\/AJCP3J1ZKYBFQXJM","article-title":"Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization","volume":"137","author":"Fritsma","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_15","first-page":"601","article-title":"Evaluation of a modified procedure for Staclot LA for the confirmation of lupus anticoagulants","volume":"5","author":"Charles","year":"1994","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.thromres.2006.10.015","article-title":"Evaluation of a new silica clotting time in the diagnosis of lupus anticoagulants","volume":"120","author":"Devreese","year":"2007","journal-title":"Thromb. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/ajh.21780","article-title":"Screening coagulation testing using the APTT: Which reagent to choose?","volume":"85","author":"Dembitzer","year":"2010","journal-title":"Am. J. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1111\/j.1538-7836.2012.04906.x","article-title":"APTT reagent with ellagic acid as activator shows adequate lupus anticoagulant sensitivity in comparison to silica-based reagent","volume":"10","author":"Kumano","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/ijlh.12227","article-title":"Commonalities and contrasts in recent guidelines for lupus anticoagulant detection","volume":"36","author":"Moore","year":"2014","journal-title":"Int. J. Lab. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1046\/j.1365-2141.2002.03821.x","article-title":"UK National External Quality Assessment Scheme for Blood Coagulation. Lupus anticoagulant testing: Improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods","volume":"119","author":"Jennings","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1160\/TH08-06-0353","article-title":"Are laboratories following published recommendations for lupus anticoagulant testing? An international evaluation of practices","volume":"101","author":"Moffat","year":"2009","journal-title":"Thromb. Haemost."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1309\/AJCP4SPPLG5XVIXF","article-title":"Lupus anticoagulant testing: Performance and practices by North American clinical laboratories","volume":"134","author":"Dembitzer","year":"2010","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1055\/s-0037-1614567","article-title":"The sensitivity and specificity of commercial reagents for the detection of lupus anticoagulant show marked differences in performance between photo-optical and mechanical coagulometers","volume":"81","author":"Lawrie","year":"1999","journal-title":"Thromb. Haemost."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00001721-200404000-00015","article-title":"Heterogeneity of Russell\u2019s viper venom affects the sensitivity of the dilute Russell\u2019s viper venom time to lupus anticoagulants","volume":"15","author":"Moore","year":"2004","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1055\/s-0033-1334865","article-title":"Comparison of six dilute russell viper venom time lupus anticoagulant screen\/confirm assay kits","volume":"39","author":"McGlasson","year":"2013","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Depreter, B., and Devreese, K.M. (2016). Dilute Russell\u2019s viper venom time reagents in lupus anticoagulant testing: A well-considered choice. Clin. Chem. Lab. Med.","DOI":"10.1515\/cclm-2016-0245"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0049-3848(01)00420-0","article-title":"Dilute prothrombin-time based lupus ratio test. Integrated LA testing with recombinant tissue thromboplastin","volume":"105","author":"Jacobsen","year":"2002","journal-title":"Thromb. Res."},{"key":"ref_28","first-page":"673","article-title":"A new lupus anticoagulant test based on dilute prothrombin time","volume":"114","author":"Mackie","year":"2004","journal-title":"Thromb. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.thromres.2008.04.005","article-title":"Evaluation of a new commercial dilute prothrombin time in the diagnosis of lupus anticoagulants","volume":"123","author":"Devreese","year":"2008","journal-title":"Thromb. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00001721-200204000-00013","article-title":"The Activated Seven Lupus Anticoagulant (ASLA) assay: A new test for lupus anticoagulants (LAs). Evidence that some LAs are detectable only in extrinsic pathway based assays","volume":"13","author":"Moore","year":"2002","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1055\/s-0038-1649701","article-title":"The Textarin\/Ecarin ratio: A confirmatory test for lupus anticoagulants","volume":"70","author":"Triplett","year":"1993","journal-title":"Thromb. Haemost."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/MBC.0000000000000486","article-title":"Taipan snake venom time coupled with ecarin time enhances lupus anticoagulant detection in non-anticoagulated patients","volume":"27","author":"Moore","year":"2016","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/blood-2012-03-378646","article-title":"The significance of autoantibodies against \u03b22-glycoprotein I","volume":"120","author":"Urbanus","year":"2012","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.mbc.0000061283.28953.39","article-title":"The Ecarin time is an improved confirmatory test for the Taipan snake venom time in warfarinised patients with lupus anticoagulants","volume":"14","author":"Moore","year":"2003","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood-2007-01-066043","article-title":"Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study","volume":"110","author":"Galli","year":"2007","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/1076029607305099","article-title":"The activated seven lupus anticoagulant assay detects clinically significant antibodies","volume":"14","author":"Moore","year":"2008","journal-title":"Clin. Appl. Thromb. Haemost."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/j.1538-7836.2011.04420.x","article-title":"Lupus anticoagulant: Performance of the tests as recommended by the latest ISTH guidelines","volume":"9","author":"Swadzba","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"ref_38","first-page":"1511","article-title":"Differences in lupus anticoagulant final conclusion through clotting time or Rosner index for mixing test interpretation","volume":"54","author":"Depreter","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1515\/cclm-2012-0382","article-title":"Cooperation experience in a multicentre study to define the upper limits in a normal population for the diagnostic assessment of the functional lupus anticoagulant assays","volume":"51","author":"Pradella","year":"2013","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/asheducation-2014.1.321","article-title":"Laboratory methods to detect antiphospholipid antibodies","volume":"2014","author":"Krilis","year":"2014","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/ijlh.12006","article-title":"Lupus anticoagulant detection: Out of control?","volume":"35","author":"Moore","year":"2013","journal-title":"Int. J. Lab. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1365-2141.2000.02466.x","article-title":"The importance of locally derived reference ranges and standardized calculation of dilute Russell\u2019s viper venom time results in screening for lupus anticoagulant","volume":"111","author":"Gardiner","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/107602960200800206","article-title":"Reference intervals of the dilute tissue thromboplastin inhibition and dilute Russell\u2019s viper venom tests revisited","volume":"8","author":"Gerbutavicius","year":"2002","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_44","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2008). Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory: Approved Guideline, Clinical and Laboratory Standards Institute. [3rd ed.]. CLSI Document EP28-A3c."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1751-553X.2011.01376.x","article-title":"New guidelines for lupus anticoagulant: Sensitivity and specificity of cut-off values calculated with plasmas from healthy controls in mixing and confirmatory tests","volume":"34","author":"Martinuzzo","year":"2012","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1111\/jth.12345","article-title":"Index of circulating anticoagulant cut-off value establishment in activated partial thromboplastin time mixing test for lupus anticoagulant diagnosis","volume":"11","author":"Kumano","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1177\/0961203315617540","article-title":"Diagnostic accuracy of silica clotting time method for lupus anticoagulant in a clinical population with various symptoms of antiphospholipid syndrome","volume":"25","author":"Averina","year":"2016","journal-title":"Lupus"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/ejh.12634","article-title":"Applying a direct aPTT ratio (PlatelinLS\/ActinFS) permits to identify rapidly and reliably a bleeding-related factor deficiency or a lupus anticoagulant sequential to an isolated prolongation of aPTT in paediatric pre-operative screening","volume":"96","author":"Li","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/MBC.0000000000000463","article-title":"Dilute Russell\u2019s viper venom and activated partial thromboplastin time in lupus anticoagulant diagnosis: Is mixing essential?","volume":"27","author":"Chandrashekar","year":"2016","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2004.01028.x","article-title":"UK National External Quality Assessment Scheme for Blood Coagulation. Lupus anticoagulant testing using plasma spiked with monoclonal antibodies: Performance in the UK NEQAS proficiency testing programme","volume":"2","author":"Jennings","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0961203312446389","article-title":"In ECAT veritas?","volume":"21","author":"Reber","year":"2012","journal-title":"Lupus"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0049-3848(96)00094-1","article-title":"False negative screening tests for lupus anticoagulants\u2014An unrecognised problem?","volume":"82","author":"Jacobsen","year":"1996","journal-title":"Thromb. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.thromres.2007.05.018","article-title":"Further evidence of false negative screening for lupus anticoagulants","volume":"121","author":"Moore","year":"2008","journal-title":"Thromb. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/j.1538-7836.2010.03807.x","article-title":"No more mixing tests required for integrated assay systems in the laboratory diagnosis of lupus anticoagulants","volume":"8","author":"Devreese","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1055\/s-0032-1304717","article-title":"To mix or not to mix in lupus anticoagulant testing? That is the question","volume":"38","author":"Tripodi","year":"2012","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/MBC.0b013e328358e899","article-title":"Clinical significance of the mixing test in laboratory diagnoses of lupus anticoagulant: The fate of the mixing test in integrated lupus anticoagulant test systems","volume":"23","author":"Hong","year":"2012","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1160\/TH14-02-0122","article-title":"Optimisation of lupus anticoagulant tests: Should test samples always be mixed with normal plasma?","volume":"112","author":"Pennings","year":"2014","journal-title":"Thromb. Haemost."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-0037-1613777","article-title":"Transient lupus anticoagulants in children: Stepwise disappearance of diagnostic features","volume":"83","author":"Male","year":"2000","journal-title":"Thromb. Haemost."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1111\/j.1538-7836.2003.0543h.x","article-title":"Normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulant","volume":"1","author":"Thom","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.thromres.2005.09.010","article-title":"The dilution effect of equal volume mixing studies compromises confirmation of inhibition by lupus anticoagulants even when mixture specific reference ranges are applied","volume":"118","author":"Moore","year":"2006","journal-title":"Thromb. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/jth.13020","article-title":"Mixing studies in lupus anticoagulant testing are required at least in some type of samples","volume":"13","author":"Devreese","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/ijlh.12138","article-title":"Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin","volume":"36","author":"Martinuzzo","year":"2014","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-9560-5-12","article-title":"Combining Taipan snake venom time\/Ecarin time screening with the mixing studies of conventional assays increases detection rates of lupus anticoagulants in orally anticoagulated patients","volume":"5","author":"Moore","year":"2007","journal-title":"Thromb. J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/j.1538-7836.2010.04090.x","article-title":"Laboratory investigation of lupus anticoagulants: Mixing studies are sometimes required","volume":"8","author":"Favaloro","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1160\/TH12-11-0850","article-title":"Laboratory diagnostic outcome applying detection criteria recommended by the Scientific and Standardization Committee of the ISTH on Lupus Anticoagulant","volume":"110","author":"Chantarangkul","year":"2013","journal-title":"Thromb. Haemost."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/ajcp\/95.3.408","article-title":"Evaluation of different mixing study reagents and dilution effect in lupus anticoagulant testing","volume":"95","author":"Kaczor","year":"1991","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1055\/s-0033-1336832","article-title":"Mixing tests: Diagnostic aides in the investigation of prolonged prothrombin times and activated partial thromboplastin times","volume":"39","author":"Kershaw","year":"2013","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.thromres.2016.01.019","article-title":"Mixing test specific cut-off is more sensitive at detecting lupus anticoagulants than index of circulating anticoagulant","volume":"139","author":"Moore","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1055\/s-0038-1651083","article-title":"Detection and quantitative evaluation of lupus circulating anticoagulant activity","volume":"57","author":"Rosner","year":"1987","journal-title":"Thromb. Haemost."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/PAT.0000000000000142","article-title":"Antiphospholipid antibody testing for the antiphospholipid syndrome: A comprehensive practical review including a synopsis of challenges and recent guidelines","volume":"46","author":"Favaloro","year":"2014","journal-title":"Pathology"},{"key":"ref_71","first-page":"627","article-title":"Detection of lupus anticoagulant by means of dilute Russell\u2019s viper venom time is affected by oral anticoagulant therapy","volume":"1","author":"Jouhikainen","year":"1990","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_72","first-page":"138","article-title":"Warfarin does not interfere with lupus anticoagulant detection by dilute Russell\u2019s viper venom time","volume":"55","author":"Olteanu","year":"2009","journal-title":"Clin. Lab."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/bjh.13030","article-title":"Lupus anticoagulant testing and anticoagulation do not mix: Quantitation of discrepant results and potential approaches to reduce false positives","volume":"167","author":"Chandler","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/ijlh.12409","article-title":"Screening for lupus anticoagulants in patients treated with vitamin K antagonists","volume":"37","author":"Isert","year":"2015","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/j.1538-7836.2011.04395.x","article-title":"Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time","volume":"9","author":"Kamphuisen","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/jcp.47.6.497","article-title":"The Taipan snake venom time: A new test for lupus anticoagulant","volume":"47","author":"Rooney","year":"1994","journal-title":"J. Clin. Pathol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1006\/jaut.2000.0392","article-title":"Conceptions and misconceptions in testing for lupus anticoagulants","volume":"15","author":"Exner","year":"2000","journal-title":"J. Autoimmun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/bjh.12975","article-title":"BCSH committee. Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology","volume":"166","author":"Kitchen","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Thomas, O., Lybeck, E., Strandberg, K., Tynng\u00e5rd, N., and Sch\u00f6tt, U. (2015). Monitoring low molecular weight heparins at therapeutic levels: Dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0116835"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"967","DOI":"10.5858\/arpa.2012-0236-OA","article-title":"Direct thrombin inhibitors and factor Xa inhibitors can influence the diluted prothrombin time used as the initial screen for lupus anticoagulant","volume":"137","author":"Olah","year":"2013","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/ijlh.12528","article-title":"Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays","volume":"38","author":"Gosselin","year":"2016","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1160\/TH16-02-0081","article-title":"Lupus-anticoagulant testing at NOAC trough levels","volume":"116","author":"Ratzinger","year":"2016","journal-title":"Thromb. Haemost."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/labmed\/lmw029","article-title":"Rivaroxaban Therapy, False-Positive Lupus Anticoagulant Screening Results, and Confirmatory Assay Results","volume":"47","author":"Murer","year":"2016","journal-title":"Lab. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/jth.12917","article-title":"Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome","volume":"13","author":"Arachchillage","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1160\/TH10-08-0511","article-title":"Rivaroxaban and false positive lupus anticoagulant testing","volume":"105","author":"Merriman","year":"2011","journal-title":"Thromb. Haemost."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/jth.12649","article-title":"Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays","volume":"12","author":"Hillarp","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/MBC.0000000000000235","article-title":"False-positive lupus anticoagulant in patients receiving rivaroxaban: 24 h since the last dose are needed to exclude antiphospholipid syndrome","volume":"26","author":"Iwaniec","year":"2015","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_88","first-page":"85","article-title":"Evaluation of a new formulation dilute Russell\u2019s viper venom time for detection of lupus anticoagulants","volume":"14","author":"Moore","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/MBC.0000000000000247","article-title":"Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism","volume":"26","author":"Sciascia","year":"2015","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1111\/ijlh.12319","article-title":"The effects of dabigatran on lupus anticoagulant, diluted plasma thrombin time, and other specialized coagulation assays","volume":"37","author":"Kim","year":"2015","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/PAT.0000000000000252","article-title":"The effect of dabigatran on haemostasis tests: A comprehensive assessment using in vitro and ex vivo samples","volume":"47","author":"Bonar","year":"2015","journal-title":"Pathology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/jth.13138","article-title":"The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders","volume":"13","author":"Jacquemin","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1182\/blood-2009-09-244426","article-title":"Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants","volume":"115","author":"Devreese","year":"2010","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0049-3848(93)90049-T","article-title":"A quantitative, semi-automated and computer-assisted test for lupus anticoagulant","volume":"69","author":"Schjetlein","year":"1993","journal-title":"Thromb. Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1055\/s-0037-1613896","article-title":"The Lupus Ratio Test\u2014An interlaboratory study on the detection of lupus anticoagulants by an APTT-based, integrated, and semi-quantitative test","volume":"83","author":"Jacobsen","year":"2000","journal-title":"Thromb. Haemost."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1055\/s-0037-1616090","article-title":"Quantification of lupus anticoagulants in clinical samples using anti-beta2GP1 and anti-prothrombin monoclonal antibodies","volume":"86","author":"Arnout","year":"2001","journal-title":"Thromb. Haemost."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1182\/blood-2006-07-030148","article-title":"Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5","volume":"109","author":"Wu","year":"2007","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1177\/0961203312438114","article-title":"Standardization of lupus anticoagulant. The Lupus Anticoagulant Sensitivity Index (LASI)","volume":"21","author":"Tripodi","year":"2012","journal-title":"Lupus"},{"key":"ref_99","first-page":"85","article-title":"Mixing test specific cut-off is more sensitive at detecting in vitro lupus anticoagulant inhibition than the index of circulating anticoagulant with multiple APTT and dRVVT reagents","volume":"14","author":"Kumano","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Brusch, A. (2016). The significance of anti-beta-2-glycoprotein I antibodies in antiphospholipid syndrome. Antibodies, 5.","DOI":"10.3390\/antib5020016"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1177\/0961203316640366","article-title":"Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome","volume":"25","author":"Mahler","year":"2016","journal-title":"Lupus"}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/5\/4\/22\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:27:51Z","timestamp":1760210871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/5\/4\/22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":101,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,12]]}},"alternative-id":["antib5040022"],"URL":"https:\/\/doi.org\/10.3390\/antib5040022","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}